

ASX ANNOUNCEMENT

3 April 2025

Biome secures \$5.0 million debt facilities with NAB

- *\$5.0m debt facility secured to accelerate growth*
- *Funding facility is non-dilutive to shareholders*
- *NAB facility comprises:*
 - \$3.5m NAB Invoice Finance Facility
 - \$1.5m NAB Trade Finance Facility

Microbiome health company **Biome Australia Limited** (ASX: BIO) ('Biome' or 'the company') is pleased to announce that its wholly owned subsidiary, *Biome Australia Trading Pty Ltd* ("*Biome Trading*") has entered into a \$5.0 million secured debt facility ("Facility") with National Australia Bank (NAB) to accelerate growth. This facility will replace the existing debt facility with Tradeplus24 (TP24), announced on the ASX on 28 June 2023 at a significantly improved interest rate.

Biome worked closely with NAB Health throughout their due diligence and risk assessment of *Biome's* business over the past four months and is very pleased to achieve the trust and backing of one of Australia's leading banks in NAB, Australia's biggest business bank, with the signing of this debt facility.

Biome will utilise this facility to continually optimise inventory management and support the growth of the business both locally and internationally as volumes continue to increase. The use of this facility toward investment in inventory will allow for improvement in supply chain efficiencies and cost of goods sold (COGS).

The NAB facility is divided into two components:

\$3.5m NAB Invoice Finance Facility

This facility will provide invoice funding for Biome's Australian accounts receivables. The current interest rate of the facility is 7.75%, a significant improvement on Biome's previous facility. The facility carries an application fee of \$12,250 plus a monthly facility fee of \$1,700. This is an ongoing facility with no set expiry date.

\$1.5m NAB Trade Refinance Facility

The current interest rate of the facility is 7.53% p.a. The facility carries an application fee of \$5,250 plus a facility fee of \$1.3% p.a. This facility is set to expire on 27 February 2026, with the intention to have the term of the facility extended before expiry.

The facility is secured by a General Security Agreement over the whole of Biome Trading's assets, a first ranking priority charge over the whole of Biome Trading's receivables (debtor) book and a Deed of Guarantee and Indemnity from the Company, supported by a General Security Agreement over the whole of the assets of the Company.

Biome Australia's Chief Financial Officer, Douglas Loh, commented:

"I am delighted we have formed this new partnership with NAB Health, a division of one of Australia's leading business banks. NAB's specialty healthcare department has a deep understanding of the Australian health industry, and their backing is a significant validation of the Biome Australia business. As we continue to expand Biome internationally, we look forward to working closely with the NAB Health team to support our growth capital needs."

-ENDS-


Approved for release by the Biome Australia board of directors.

About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics[®].

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild



eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations

Lauren

+61 (3) 9017 5800

corporate@biomeaustralia.com

Media enquiries

media@activated.co

Forward looking statements

*This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (**Forward Looking Statements**).*

Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward Looking Statements containing forward looking financial information provided in this release is for illustrative purposes only and is not represented as being indicative of Biome's views on its future financial condition and/or performance.

Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or results expressed or implied in any Forward Looking Statements) contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.



Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.



Biome Australia Trading Pty Ltd
192-194 Johnston Street
Collingwood VIC 3066

+61 3 9017 5800
support@activated.co
biomeaustralia.com

ASX:BIO
ACN 627 364 014

